{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:41:44Z","timestamp":1791650504246,"version":"4.3.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Fujian Provincial Clinical Research Center for Type 2 Diabetes","award":["2022Y2013"],"award-info":[{"award-number":["2022Y2013"]}]},{"name":"Department of Endocrinology (National Clinical Key Specialty\uff09","award":["2023001"],"award-info":[{"award-number":["2023001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-025-02595-4","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T04:20:08Z","timestamp":1745986808000},"page":"1951-1965","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and safety of Tocilizumab for thyroid eye disease: a systemic review and Meta-analysis"],"prefix":"10.1007","volume":"48","author":[{"given":"Shuzhen","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangchun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5650-5281","authenticated-orcid":false,"given":"Junping","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"2595_CR1","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/joim.13524","volume":"292","author":"L Bartalena","year":"2022","unstructured":"Bartalena L, Tanda ML (2022) Current concepts regarding graves\u2019 orbitopathy. J Intern Med 292:692\u2013716. https:\/\/doi.org\/10.1111\/joim.13524","journal-title":"J Intern Med"},{"key":"2595_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/cen.14296","volume":"93","author":"YH Chin","year":"2020","unstructured":"Chin YH, Ng CH, Lee MH, Koh JWH, Kiew J, Yang SP, Sundar G, Khoo CM (2020) Prevalence of thyroid eye disease in graves\u2019 disease: A meta-analysis and systematic review. Clin Endocrinol (Oxf) 93:363\u2013374. https:\/\/doi.org\/10.1111\/cen.14296","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2595_CR3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ecl.2021.12.004","volume":"51","author":"TD Hoang","year":"2022","unstructured":"Hoang TD, Stocker DJ, Chou EL, Burch HB (2022) 2022 Update on clinical management of graves disease and thyroid eye disease. Endocrinol Metab Clin North Am 51:287\u2013304. https:\/\/doi.org\/10.1016\/j.ecl.2021.12.004","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2595_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/s2213-8587(16)30046-8","volume":"5","author":"WM Wiersinga","year":"2017","unstructured":"Wiersinga WM (2017) Advances in treatment of active, moderate-to-severe graves\u2019 ophthalmopathy. Lancet Diabetes Endocrinol 5:134\u2013142. https:\/\/doi.org\/10.1016\/s2213-8587(16)30046-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2595_CR5","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1210\/jc.2016-1315","volume":"101","author":"CC Krieger","year":"2016","unstructured":"Krieger CC, Place RF, Bevilacqua C, Marcus-Samuels B, Abel BS, Skarulis MC, Kahaly GJ, Neumann S, Gershengorn MC (2016) TSH\/IGF-1 receptor cross talk in graves\u2019 ophthalmopathy pathogenesis. J Clin Endocrinol Metab 101:2340\u20132347. https:\/\/doi.org\/10.1210\/jc.2016-1315","journal-title":"J Clin Endocrinol Metab"},{"key":"2595_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41574-019-0305-4","volume":"16","author":"PN Taylor","year":"2020","unstructured":"Taylor PN, Zhang L, Lee RWJ, Muller I, Ezra DG, Dayan CM, Kahaly GJ, Ludgate M (2020) New insights into the pathogenesis and nonsurgical management of graves orbitopathy. Nat Rev Endocrinol 16:104\u2013116. https:\/\/doi.org\/10.1038\/s41574-019-0305-4","journal-title":"Nat Rev Endocrinol"},{"key":"2595_CR7","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/eje-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marin\u00f2 M, Vaidya B, Wiersinga WM (2021) The 2021 European group on graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of graves\u2019 orbitopathy. Eur J Endocrinol 185:G43\u2013g67. https:\/\/doi.org\/10.1530\/eje-21-0479","journal-title":"Eur J Endocrinol"},{"key":"2595_CR8","doi-asserted-by":"publisher","first-page":"204201882095833","DOI":"10.1177\/2042018820958335","volume":"11","author":"J L\u00e4ngericht","year":"2020","unstructured":"L\u00e4ngericht J, Kr\u00e4mer I, Kahaly GJ (2020) Glucocorticoids in graves\u2019 orbitopathy: mechanisms of action and clinical application. Ther Adv Endocrinol Metab 11:2042018820958335. https:\/\/doi.org\/10.1177\/2042018820958335","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2595_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1507\/endocrj.EJ16-0083","volume":"64","author":"Y He","year":"2017","unstructured":"He Y, Mu K, Liu R, Zhang J, Xiang N (2017) Comparison of two different regimens of intravenous Methylprednisolone for patients with moderate to severe and active graves\u2019 ophthalmopathy: a prospective, randomized controlled trial. Endocr J 64:141\u2013149. https:\/\/doi.org\/10.1507\/endocrj.EJ16-0083","journal-title":"Endocr J"},{"key":"2595_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s12020-016-0928-3","volume":"54","author":"M Moleti","year":"2016","unstructured":"Moleti M, Giuffrida G, Sturniolo G, Squadrito G, Campenn\u00ec A, Morelli S, Puxeddu E, Sisti E, Trimarchi F, Vermiglio F, Marin\u00f2 M (2016) Acute liver damage following intravenous glucocorticoid treatment for graves\u2019 ophthalmopathy. Endocrine 54:259\u2013268. https:\/\/doi.org\/10.1007\/s12020-016-0928-3","journal-title":"Endocrine"},{"key":"2595_CR11","doi-asserted-by":"publisher","unstructured":"Zhang H, Wu S, Hu S, Fan X, Song X, Feng T, Zhou H (2024) Prediction models of intravenous glucocorticoids therapy response in thyroid eye disease. Eur Thyroid J 13. https:\/\/doi.org\/10.1530\/etj-24-0122","DOI":"10.1530\/etj-24-0122"},{"key":"2595_CR12","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1080\/14712598.2022.2066971","volume":"22","author":"B Atienza-Mateo","year":"2022","unstructured":"Atienza-Mateo B, Prieto-Pe\u00f1a D, Vicente-Rabaneda EF, Blanco R, Gonz\u00e1lez-Gay MA, Casta\u00f1eda S (2022) Utility of Tocilizumab in autoimmune eye diseases. Expert Opin Biol Ther 22:789\u2013799. https:\/\/doi.org\/10.1080\/14712598.2022.2066971","journal-title":"Expert Opin Biol Ther"},{"key":"2595_CR13","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1136\/annrheumdis-2015-207628","volume":"75","author":"GR Burmester","year":"2016","unstructured":"Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A, Dimonaco S, Mitchell N (2016) Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis 75:1081\u20131091. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207628","journal-title":"Ann Rheum Dis"},{"key":"2595_CR14","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/s0140-6736(16)00560-2","volume":"387","author":"PM Villiger","year":"2016","unstructured":"Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, B\u00fctikofer L, Seitz M, Reichenbach S (2016) Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 387:1921\u20131927. https:\/\/doi.org\/10.1016\/s0140-6736(16)00560-2","journal-title":"Lancet"},{"key":"2595_CR15","doi-asserted-by":"publisher","first-page":"Cd009226","DOI":"10.1002\/14651858.CD009226.pub3","volume":"6","author":"S Kang","year":"2022","unstructured":"Kang S, Hamed Azzam S, Minakaran N, Ezra DG (2022) Rituximab for thyroid-associated ophthalmopathy. Cochrane Database Syst Rev 6:Cd009226. https:\/\/doi.org\/10.1002\/14651858.CD009226.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"2595_CR16","doi-asserted-by":"publisher","first-page":"653627","DOI":"10.3389\/fendo.2021.653627","volume":"12","author":"TJ Smith","year":"2021","unstructured":"Smith TJ (2021) Insulin-Like growth factor pathway and the thyroid. Front Endocrinol (Lausanne) 12:653627. https:\/\/doi.org\/10.3389\/fendo.2021.653627","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2595_CR17","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73:712\u2013716. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x","journal-title":"ANZ J Surg"},{"key":"2595_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/xeb.0000000000000064","volume":"13","author":"S Moola","year":"2015","unstructured":"Moola S, Munn Z, Sears K, Sfetcu R, Currie M, Lisy K, Tufanaru C, Qureshi R, Mattis P, Mu P (2015) Conducting systematic reviews of association (etiology): the Joanna Briggs institute\u2019s approach. Int J Evid Based Healthc 13:163\u2013169. https:\/\/doi.org\/10.1097\/xeb.0000000000000064","journal-title":"Int J Evid Based Healthc"},{"key":"2595_CR19","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA (2011) The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"2595_CR20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/IOP.0000000000000037","volume":"30","author":"JV Perez-Moreiras","year":"2014","unstructured":"Perez-Moreiras JV, Alvarez-Lopez A, Gomez EC (2014) Treatment of active Corticosteroid-Resistant graves\u2019 orbitopathy. Ophthal Plast Reconstr Surg 30:162\u2013167. https:\/\/doi.org\/10.1097\/IOP.0000000000000037","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"2595_CR21","doi-asserted-by":"publisher","unstructured":"Perez-Moreiras JV, Varela-Agra M, Prada-Sanchez MC, Prada-Ramallal G (2021) Steroid-Resistant Graves\u2019 Orbitopathy Treated with Tocilizumab in Real-World Clinical Practice: A 9-Year Single-Center Experience. J Clin Med 10. https:\/\/doi.org\/10.3390\/jcm10040706","DOI":"10.3390\/jcm10040706"},{"key":"2595_CR22","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1080\/09273948.2020.1808688","volume":"30","author":"A Bennedjai","year":"2022","unstructured":"Bennedjai A, Bouheraoua N, Gatfosse M, Dupasquier-Fediaevsky L, Errera MH, Tazartes M, Borderie V, Hennocq Q, Della A, Riviere S, Heron E, Fain O, Mekinian A (2022) Tocilizumab versus rituximab in patients with moderate to severe Steroid-resistant graves\u2019 orbitopathy. Ocul Immunol Inflamm 30:500\u2013505. https:\/\/doi.org\/10.1080\/09273948.2020.1808688","journal-title":"Ocul Immunol Inflamm"},{"key":"2595_CR23","doi-asserted-by":"publisher","first-page":"1186105","DOI":"10.3389\/fendo.2023.1186105","volume":"14","author":"G Boutzios","year":"2023","unstructured":"Boutzios G, Chatzi S, Goules AV, Mina A, Charonis GC, Vlachoyiannopoulos PG, Tzioufas AG (2023) Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe graves\u2019 orbitopathy: an observational study. Front Endocrinol (Lausanne) 14:1186105. https:\/\/doi.org\/10.3389\/fendo.2023.1186105","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2595_CR24","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00417-020-04651-6","volume":"258","author":"JB Deltour","year":"2020","unstructured":"Deltour JB, d\u2019Assigny Flamen M, Ladsous M, Giovansili L, Cariou B, Caron P, Drui D, Lebranchu P (2020) Efficacy of rituximab in patients with graves\u2019 orbitopathy: a retrospective multicenter nationwide study. Graefes Arch Clin Exp Ophthalmol 258:2013\u20132021. https:\/\/doi.org\/10.1007\/s00417-020-04651-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2595_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/01676830.2022.2119262","author":"O Dorado Cortez","year":"2022","unstructured":"Dorado Cortez O, Grivet D, Perrillat N, Gain P, Thuret G (2022) Treatment of corticosteroid-resistant graves\u2019 orbitopathy with Tocilizumab: a single-centre prospective study. Orbit (London). https:\/\/doi.org\/10.1080\/01676830.2022.2119262","journal-title":"Orbit (London)"},{"key":"2595_CR26","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marin\u00f2 M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ (2020) Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 382:341\u2013352. https:\/\/doi.org\/10.1056\/NEJMoa1910434","journal-title":"N Engl J Med"},{"key":"2595_CR27","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","volume":"129","author":"RS Douglas","year":"2022","unstructured":"Douglas RS, Kahaly GJ, Ugradar S, Elflein H, Ponto KA, Fowler BT, Dailey R, Harris GJ, Schiffman J, Tang R, Wester S, Jain AP, Marcocci C, Marin\u00f2 M, Antonelli A, Eckstein A, F\u00fchrer-Sakel D, Salvi M, Sile S, Francis-Sedlak M, Holt RJ, Smith TJ (2022) Teprotumumab efficacy, safety, and durability in Longer-Duration thyroid eye disease and Re-treatment: OPTIC-X study. Ophthalmology 129:438\u2013449. https:\/\/doi.org\/10.1016\/j.ophtha.2021.10.017","journal-title":"Ophthalmology"},{"key":"2595_CR28","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1177\/1120672119845224","volume":"30","author":"L Eid","year":"2020","unstructured":"Eid L, Coste-Verdier V, Longueville E, Ribeiro E, Nicolescu-Catargi B, Korobelnik JF (2020) The effects of rituximab on graves\u2019orbitopathy: A retrospective study of 14 patients. Eur J Ophthalmol 30:1008\u20131013. https:\/\/doi.org\/10.1177\/1120672119845224","journal-title":"Eur J Ophthalmol"},{"key":"2595_CR29","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s10792-024-03143-4","volume":"44","author":"FA Habroosh","year":"2024","unstructured":"Habroosh FA, Albrashdi SS, Alsaadi AH, Eatamadi H (2024) Tocilizumab use for optic nerve compression in thyroid eye disease: a prospective longitudinal cohort. Int Ophthalmol 44:222. https:\/\/doi.org\/10.1007\/s10792-024-03143-4","journal-title":"Int Ophthalmol"},{"key":"2595_CR30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10792-024-03117-6","volume":"44","author":"C Lee","year":"2024","unstructured":"Lee C, Park JW, Kim YD, Woo KI (2024) Efficacy of Tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study. Int Ophthalmol 44:179. https:\/\/doi.org\/10.1007\/s10792-024-03117-6","journal-title":"Int Ophthalmol"},{"key":"2595_CR31","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/cen.14655","volume":"97","author":"L Moi","year":"2022","unstructured":"Moi L, Hamedani M, Ribi C (2022) Long-term outcomes in corticosteroid-refractory graves\u2019 orbitopathy treated with Tocilizumab. Clin Endocrinol (Oxf) 97:363\u2013370. https:\/\/doi.org\/10.1111\/cen.14655","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2595_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2022.05.007","author":"R Pamp\u00edn-S\u00e1nchez","year":"2022","unstructured":"Pamp\u00edn-S\u00e1nchez R, Mart\u00ednez-Mugica-Barbosa C, Fonseca-Aizpuru EM, Barbaz\u00e1n-V\u00e1zquez FJ, Fern\u00e1ndez-Gonz\u00e1lez B, Buznego-S\u00fa\u00e1rez L (2022) Outcome of Tocilizumab treatment in corticosteroid-resistant thyroid eye disease. Med Clin. https:\/\/doi.org\/10.1016\/j.medcli.2022.05.007","journal-title":"Med Clin"},{"key":"2595_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","volume":"195","author":"JV Perez-Moreiras","year":"2018","unstructured":"Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, Perez-Pampin E, Romo Lopez A, Rodr\u00edguez Alvarez FM, Castillo Laguarta JM, Del Estad Cabello A, Gessa Sorroche M, Espa\u00f1a Gregori E, Sales-Sanz M (2018) Efficacy of Tocilizumab in patients with Moderate-to-Severe Corticosteroid-Resistant graves orbitopathy: A randomized clinical trial. Am J Ophthalmol 195:181\u2013190. https:\/\/doi.org\/10.1016\/j.ajo.2018.07.038","journal-title":"Am J Ophthalmol"},{"key":"2595_CR34","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1210\/jc.2014-3014","volume":"100","author":"M Salvi","year":"2015","unstructured":"Salvi M, Vannucchi G, Curr\u00f2 N, Campi I, Covelli D, Dazzi D, Simonetta S, Guastella C, Pignataro L, Avignone S, Beck-Peccoz P (2015) Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe graves\u2019 orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 100:422\u2013431. https:\/\/doi.org\/10.1210\/jc.2014-3014","journal-title":"J Clin Endocrinol Metab"},{"key":"2595_CR35","doi-asserted-by":"publisher","unstructured":"Sanchez-Bilbao L, Martinez-Lopez D, Atienza-Mateo B, Mart\u00edn-Varillas JL, Calvo-R\u00edo V, Demetrio-Pablo R, Calder\u00f3n-Goercke M, Prieto-Pe\u00f1a D, Gonz\u00e1lez-Maz\u00f3n I, Valls-Pascual E, Valls-Espinosa B, Maiz-Alonso O, Blanco A, Torre-Salaberri I, Rodriguez-Mendez V, Garc\u00eda-Aparicio \u00c1, Veroz Gonz\u00e1lez R, Jovani V, Peiteado D, Casta\u00f1eda S, S\u00e1nchez-Orgaz M, Tomero Muriel E, De Toyos FJ, Pinillos V, Aurrecoechea E, Mora \u00c1, Conesa A, Fern\u00e1ndez M, Troyano JA, Revenga M, Hern\u00e1ndez JL, Gonz\u00e1lez-Gay MA, Blanco R (2020) Tocilizumab in graves\u2019 orbitopathy. Multicenter study of 48 patients. Annals of the Rheumatic Diseases 79:850\u2013851. https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.3651","DOI":"10.1136\/annrheumdis-2020-eular.3651"},{"key":"2595_CR36","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/iop.0000000000002027","volume":"38","author":"LD Smith","year":"2022","unstructured":"Smith LD, Moscato EE, Seiff SR (2022) Tocilizumab for the management of Thyroid-Associated orbitopathy. Ophthalmic Plast Reconstr Surg 38:188\u2013192. https:\/\/doi.org\/10.1097\/iop.0000000000002027","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"2595_CR37","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS (2017) Teprotumumab for Thyroid-Associated ophthalmopathy. N Engl J Med 376:1748\u20131761. https:\/\/doi.org\/10.1056\/NEJMoa1614949","journal-title":"N Engl J Med"},{"key":"2595_CR38","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1210\/jc.2014-2572","volume":"100","author":"MN Stan","year":"2015","unstructured":"Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS (2015) Randomized controlled trial of rituximab in patients with graves\u2019 orbitopathy. J Clin Endocrinol Metab 100:432\u2013441. https:\/\/doi.org\/10.1210\/jc.2014-2572","journal-title":"J Clin Endocrinol Metab"},{"key":"2595_CR39","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1089\/thy.2023.0167","volume":"33","author":"D Toro-Tobon","year":"2023","unstructured":"Toro-Tobon D, Rachmasari KN, Bradley EA, Wagner LH, Tooley AA, Stokken JK, Stan MN (2023) Medical therapy in patients with moderate to severe, Steroid-Resistant. Thyroid Eye Disease Thyroid 33:1237\u20131244. https:\/\/doi.org\/10.1089\/thy.2023.0167","journal-title":"Thyroid Eye Disease Thyroid"},{"key":"2595_CR40","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae711","author":"A Sun","year":"2024","unstructured":"Sun A, Wang X, Qu J, Wu Y (2024) The efficacy and safety of intravenous Tocilizumab to treat graves\u2019 ophthalmopathy: A systematic review and single-arm meta-analysis. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgae711","journal-title":"J Clin Endocrinol Metab"},{"key":"2595_CR41","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13075-022-02815-9","volume":"24","author":"C Schmitt","year":"2022","unstructured":"Schmitt C, Brockwell L, Giraudon M, Zucchetto M, Christ L, Bannert B, Daikeler T, Villiger PM (2022) Intravenous Tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging Pharmacokinetic bridging study. Arthritis Res Ther 24:133. https:\/\/doi.org\/10.1186\/s13075-022-02815-9","journal-title":"Arthritis Res Ther"},{"key":"2595_CR42","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/s1474-4422(20)30070-3","volume":"19","author":"C Zhang","year":"2020","unstructured":"Zhang C, Zhang M, Qiu W, Ma H, Zhang X, Zhu Z, Yang CS, Jia D, Zhang TX, Yuan M, Feng Y, Yang L, Lu W, Yu C, Bennett JL, Shi FD (2020) Safety and efficacy of Tocilizumab versus azathioprine in highly relapsing neuromyelitis Optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol 19:391\u2013401. https:\/\/doi.org\/10.1016\/s1474-4422(20)30070-3","journal-title":"Lancet Neurol"},{"key":"2595_CR43","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn RS (2010) Graves\u2019 ophthalmopathy. N Engl J Med 362:726\u2013738. https:\/\/doi.org\/10.1056\/NEJMra0905750","journal-title":"N Engl J Med"},{"key":"2595_CR44","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1080\/01676830.2018.1435694","volume":"37","author":"I Pascual-Camps","year":"2018","unstructured":"Pascual-Camps I, Molina-Pallete R, Bort-Mart\u00ed MA, Todol\u00ed J, Espa\u00f1a-Gregori E (2018) Tocilizumab as first treatment option in optic neuropathy secondary to graves\u2019 orbitopathy. Orbit 37:450\u2013453. https:\/\/doi.org\/10.1080\/01676830.2018.1435694","journal-title":"Orbit"},{"key":"2595_CR45","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s40618-023-02036-0","volume":"46","author":"M Pelewicz-Sowa","year":"2023","unstructured":"Pelewicz-Sowa M, Mi\u015bkiewicz P (2023) Dysthyroid optic neuropathy: emerging treatment strategies. J Endocrinol Invest 46:1305\u20131316. https:\/\/doi.org\/10.1007\/s40618-023-02036-0","journal-title":"J Endocrinol Invest"},{"key":"2595_CR46","doi-asserted-by":"publisher","unstructured":"Burch HB, Perros P, Bednarczuk T, Cooper DS, Dolman PJ, Leung AM, Mombaerts I, Salvi M, Stan MN (2022) Management of thyroid eye disease: a consensus statement by the American thyroid association and the European thyroid association. Eur Thyroid J 11. https:\/\/doi.org\/10.1530\/etj-22-0189","DOI":"10.1530\/etj-22-0189"},{"key":"2595_CR47","doi-asserted-by":"publisher","first-page":"Cd012984","DOI":"10.1002\/14651858.CD012984.pub2","volume":"11","author":"S Hamed Azzam","year":"2018","unstructured":"Hamed Azzam S, Kang S, Salvi M, Ezra DG (2018) Tocilizumab for thyroid eye disease. Cochrane Database Syst Rev 11:Cd012984. https:\/\/doi.org\/10.1002\/14651858.CD012984.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"2595_CR48","doi-asserted-by":"publisher","first-page":"e050337","DOI":"10.1136\/bmjopen-2021-050337","volume":"12","author":"J Ko","year":"2022","unstructured":"Ko J, Kook KH, Yoon JS, Woo KI, Yang JW (2022) Longitudinal association of thyroid-stimulating Immunoglobulin levels with clinical characteristics in thyroid eye disease. BMJ Open 12:e050337. https:\/\/doi.org\/10.1136\/bmjopen-2021-050337","journal-title":"BMJ Open"},{"key":"2595_CR49","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1210\/clinem\/dgac328","volume":"107","author":"TJ Smith","year":"2022","unstructured":"Smith TJ (2022) Understanding pathogenesis intersects with effective treatment for thyroid eye disease. J Clin Endocrinol Metab 107:S13\u2013s26. https:\/\/doi.org\/10.1210\/clinem\/dgac328","journal-title":"J Clin Endocrinol Metab"},{"key":"2595_CR50","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/iop.0000000000002573","volume":"40","author":"AF Duarte","year":"2024","unstructured":"Duarte AF, Xavier NF, Sales Sanz M, Cruz AAV (2024) Efficiency and safety of Tocilizumab for the treatment of thyroid eye disease: A systematic review. Ophthalmic Plast Reconstr Surg 40:367\u2013373. https:\/\/doi.org\/10.1097\/iop.0000000000002573","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"2595_CR51","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4103\/sjopt.sjopt_176_22","volume":"37","author":"WA Fatani","year":"2023","unstructured":"Fatani WA, Hamdan DM, Taher NO, Alsharef JF, Aldubi RM, Alwagdani AM, Alhothali TN, Khan ZU (2023) Monoclonal antibodies for the treatment of graves\u2019 ophthalmopathy: A systematic review and meta-analysis. Saudi J Ophthalmol 37:137\u2013148. https:\/\/doi.org\/10.4103\/sjopt.sjopt_176_22","journal-title":"Saudi J Ophthalmol"},{"key":"2595_CR52","doi-asserted-by":"publisher","first-page":"1160936","DOI":"10.3389\/fendo.2023.1160936","volume":"14","author":"Y Hu","year":"2023","unstructured":"Hu Y, Chen J, Lin K, Yu X (2023) Efficacy and safety of intravenous monoclonal antibodies in patients with moderate-to-severe active graves\u2019ophthalmopathy: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 14:1160936. https:\/\/doi.org\/10.3389\/fendo.2023.1160936","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2595_CR53","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/jmv.25907","volume":"92","author":"AR Morrison","year":"2020","unstructured":"Morrison AR, Johnson JM, Ramesh M, Bradley P, Jennings J, Smith ZR (2020) Acute hypertriglyceridemia in patients with COVID-19 receiving Tocilizumab. J Med Virol 92:1791\u20131792. https:\/\/doi.org\/10.1002\/jmv.25907","journal-title":"J Med Virol"},{"key":"2595_CR54","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/14740338.2017.1303479","volume":"16","author":"SH Machado","year":"2017","unstructured":"Machado SH, Xavier RM (2017) Safety of Tocilizumab in the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf 16:493\u2013500. https:\/\/doi.org\/10.1080\/14740338.2017.1303479","journal-title":"Expert Opin Drug Saf"},{"key":"2595_CR55","doi-asserted-by":"publisher","first-page":"R141","DOI":"10.1186\/ar3455","volume":"13","author":"MH Schiff","year":"2011","unstructured":"Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF (2011) Integrated safety in Tocilizumab clinical trials. Arthritis Res Ther 13:R141. https:\/\/doi.org\/10.1186\/ar3455","journal-title":"Arthritis Res Ther"},{"key":"2595_CR56","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s40265-022-01804-1","volume":"82","author":"T Nie","year":"2022","unstructured":"Nie T, Lamb YN (2022) Teprotumumab: A review in thyroid eye disease. Drugs 82:1663\u20131670. https:\/\/doi.org\/10.1007\/s40265-022-01804-1","journal-title":"Drugs"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02595-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02595-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02595-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T20:02:29Z","timestamp":1756584149000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02595-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":56,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["2595"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02595-4","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"17 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}